When was Msics Pharma founded?

Msics Pharma was founded in 2020 and raised its 1st funding round 6 years after it was founded.

Where is Msics Pharma located?

Msics Pharma is headquartered in Tel Aviv, Israel.

How many employees does Msics Pharma have?

As of May 31, 2026, the latest employee count at Msics Pharma is 7.

Is Msics Pharma a funded company?

Msics Pharma is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on May 05, 2026.

When was the latest funding round of Msics Pharma?

Msics Pharma's latest funding was a $***** Series A round on May 05, 2026, with participation from 3 investors. Its primary sector is Neurology. In Israel, the Neurology sector has seen $58.7M in funding in 2026 to date.

Where does Msics Pharma rank among its competitors?

Msics Pharma ranks 20th amongst 31 active competitors, of which 10 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Psilera, which secured $8.8M in May, 2026.

Who are the top competitors of Msics Pharma?

Msics Pharma's top competitors include COMPASS Pathways, Delix Therapeutics and Gilgamesh. Among them, Psilera secured the most recent funding round in May, 2026.

Msics Pharma - 2026 Company Profile, Funding & Competitors

Msics Pharma is a series A company based in Tel Aviv (Israel), founded in 2020. It operates as a Developer of naturally-sourced psilocybin products for pharmaceutical applications and clinical trials. Msics Pharma has raised $3.6M in funding from FUSION. The company has 31 active competitors, including 10 funded and 14 that have exited. Its top competitors include companies like COMPASS Pathways, Delix Therapeutics and Gilgamesh.

Company Details

Developer of naturally-sourced psilocybin products for pharmaceutical applications and clinical trials. The company operates a production facility producing a flagship psilocybin product. This product is undergoing trials to treat medical conditions. The company is recruiting patients for clinical trials in depression, OCD, anorexia, and PTSD.

Key Metrics

Founded Year

2020

Location

Tel Aviv, Israel

Stage

Series A

Total Funding

$3.6M in 1 round

Latest Funding Round

Series A, May 05, 2026, $*****

Investors

FUSION & 5 more

Ranked

20^th among 31 active competitors

Employee Count

7 as on May 31, 2026

Similar Companies

COMPASS Pathways & 37 more

View Msics Pharma's full profile

Msics Pharma has raised a total funding of $3.6M over 1 round. Its latest funding round was a Series A round on May 05, 2026 for $*****. 3 investors participated in its latest round. Msics Pharma has 4 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Msics Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 05, 2026	9463997	Series A	8255033	3500659	5803645	3553612

Access funding benchmarks and valuations. Sign up today!

View details of Msics Pharma's funding rounds and investors

Msics Pharma's employee count trend

Msics Pharma has 7 employees as of May 26. Here is Msics Pharma's employee count trend over the years:

Uncover Msics Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Msics Pharma include COMPASS Pathways, Delix Therapeutics and Gilgamesh. Here is the list of Top 10 competitors of Msics Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	COMPASS Pathways 2016, London (United Kingdom), Public	Developer of therapies for treating mental disorders	$109M	Perceptive Advisors, Able Partners & 20 others	67/100
2nd	Delix Therapeutics 2019, Menlo Park (United States), Series A	Developer of therapeutic solutions for the treatment of multiple neurological disorders	$100M	RA Capital Management, Artis Ventures & 22 others	61/100
3rd	Gilgamesh 2019, New York City (United States), Series B	Developer of drugs for neuropsychiatric conditions	$152M	Prime Movers Lab, Y Combinator & 18 others	59/100
4th	MindMed 2019, New York City (United States), Public	Developer of psychedelic-based therapies for brain health disorders	-	TR Ventures, K2 HealthVentures & 8 others	58/100
5th	Cybin 2002, Toronto (Canada), Public	Provider of psychedelic therapeutics for psychiatric disorders	-	Hightrailcapital, Subversive Capital & 10 others	56/100
6th	CB Therapeutics 2015, San Diego (United States), Series A	Provider of biosynthetic cannabinoids from sugar	$150K	EvoNexus, LYVC & 7 others	54/100
7th	Neural Therapeutics 2020, Toronto (Canada), Public	Developer of ethnobotanical drug for neurological disorder	$495K	-	48/100
8th	Tryp Therapeutics 2020, Kelowna (Canada), Public	Developer of therapeutic solutions for treating neuropsychiatric disorders & pain	-	-	48/100
9th	Psyence 1997, Toronto (Canada), Public	Developer of psychedelic therapeutics for mental health disorders	-	-	47/100
10th	Psilera 2019, Tampa (United States), Seed	Manufacturer of natural-based medicines for the treatment of mental health illnesses	$11.3M	Iter Investments, What If Ventures & 2 others	46/100
20th	Msics Pharma 2020, Tel Aviv (Israel), Series A	Developer of naturally-sourced psilocybin products for pharmaceutical applications and clinical trials	$3.6M	FUSION, GlenRock Israel & 4 others	35/100